BioCentury | Jan 25, 2016
Company News

OncoFusion Therapeutics, Medivation deal

...terms and whether any parts of the deal are ongoing (see BioCentury, April 28, 2014). OncoFusion Therapeutics Inc....
BioCentury | Jan 16, 2016
Company News

OncoFusion reacquires BET candidates

OncoFusion Therapeutics Inc. (Ann Arbor, Mich.) said it reacquired rights from Medivation Inc. (NASDAQ:MDVN) to "certain compounds" targeting the BET bromodomain superfamily. OncoFusion said it plans to begin clinical trials of at least one candidate....
BioCentury | Jul 31, 2014
Targets & Mechanisms

Taking a BET on hedgehog

...and an investigator at the Howard Hughes Medical Institute . He also is cofounder of OncoFusion Therapeutics Inc....
...NASDAQ:MDVN), San Francisco, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Oncoethix S.A. , Lausanne, Switzerland Oncofusion Therapeutics Inc....
BioCentury | May 8, 2014
Cover Story

BETting on OncoFusion

...with a new way to disrupt androgen receptor signaling. The company got the molecules from OncoFusion Therapeutics Inc....
...Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Memorial Sloan Kettering Cancer Center , New York, N.Y. OncoFusion Therapeutics Inc....
BioCentury | May 8, 2014
Distillery Therapeutics

Indication: Cancer

...Pharma Inc. market Xtandi to treat prostate cancer. The corresponding author is a cofounder of OncoFusion Therapeutics Inc....
BioCentury | Apr 28, 2014
Company News

Medivation, OncoFusion Therapeutics deal

...Tokyo, Japan) market Xtandi, an oral androgen receptor antagonist. Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. OncoFusion Therapeutics Inc....
BioCentury | Apr 28, 2014
Finance

Highlights of weekly biotech stock moves

...week. Medivation Inc. (NASDAQ:MDVN) was off $0.24 to $57.69 last week after receiving access to OncoFusion Therapeutics Inc....
BioCentury | Apr 25, 2014
Company News

Medivation, OncoFusion in bromodomain deal

OncoFusion Therapeutics Inc. (Ann Arbor, Mich.) granted Medivation Inc. (NASDAQ:MDVN) access to OncoFusion's preclinical library of small molecule inhibitors of the BET bromodomain family. Medivation will have exclusive, worldwide rights to develop and commercialize selected...
BioCentury | Oct 10, 2013
Cover Story

NSD2 momentum

...this year, Asangani published work showing that NSD2 acts downstream of EZH2 in some cancers. OncoFusion Therapeutics Inc....
...Boston, Mass. Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, Ill. OncoFusion Therapeutics Inc....
Items per page:
1 - 9 of 9
BioCentury | Jan 25, 2016
Company News

OncoFusion Therapeutics, Medivation deal

...terms and whether any parts of the deal are ongoing (see BioCentury, April 28, 2014). OncoFusion Therapeutics Inc....
BioCentury | Jan 16, 2016
Company News

OncoFusion reacquires BET candidates

OncoFusion Therapeutics Inc. (Ann Arbor, Mich.) said it reacquired rights from Medivation Inc. (NASDAQ:MDVN) to "certain compounds" targeting the BET bromodomain superfamily. OncoFusion said it plans to begin clinical trials of at least one candidate....
BioCentury | Jul 31, 2014
Targets & Mechanisms

Taking a BET on hedgehog

...and an investigator at the Howard Hughes Medical Institute . He also is cofounder of OncoFusion Therapeutics Inc....
...NASDAQ:MDVN), San Francisco, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Oncoethix S.A. , Lausanne, Switzerland Oncofusion Therapeutics Inc....
BioCentury | May 8, 2014
Cover Story

BETting on OncoFusion

...with a new way to disrupt androgen receptor signaling. The company got the molecules from OncoFusion Therapeutics Inc....
...Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Memorial Sloan Kettering Cancer Center , New York, N.Y. OncoFusion Therapeutics Inc....
BioCentury | May 8, 2014
Distillery Therapeutics

Indication: Cancer

...Pharma Inc. market Xtandi to treat prostate cancer. The corresponding author is a cofounder of OncoFusion Therapeutics Inc....
BioCentury | Apr 28, 2014
Company News

Medivation, OncoFusion Therapeutics deal

...Tokyo, Japan) market Xtandi, an oral androgen receptor antagonist. Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. OncoFusion Therapeutics Inc....
BioCentury | Apr 28, 2014
Finance

Highlights of weekly biotech stock moves

...week. Medivation Inc. (NASDAQ:MDVN) was off $0.24 to $57.69 last week after receiving access to OncoFusion Therapeutics Inc....
BioCentury | Apr 25, 2014
Company News

Medivation, OncoFusion in bromodomain deal

OncoFusion Therapeutics Inc. (Ann Arbor, Mich.) granted Medivation Inc. (NASDAQ:MDVN) access to OncoFusion's preclinical library of small molecule inhibitors of the BET bromodomain family. Medivation will have exclusive, worldwide rights to develop and commercialize selected...
BioCentury | Oct 10, 2013
Cover Story

NSD2 momentum

...this year, Asangani published work showing that NSD2 acts downstream of EZH2 in some cancers. OncoFusion Therapeutics Inc....
...Boston, Mass. Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, Ill. OncoFusion Therapeutics Inc....
Items per page:
1 - 9 of 9